U.S., Feb. 15 -- ClinicalTrials.gov registry received information related to the study (NCT06827639) titled 'In-depth Characterization of Circulating and Infiltrating Immune Subsets and Tumor Cells in Cancer Patients' on Aug. 28, 2024.
Brief Summary: The aim of this study is to describe the tumor microenvironment of solid tumors and to understand the changes induced by anti-cancer treatments, particularly those developed by Innate Pharma. Innate Pharma is a biotechnology company which discovers and develops therapeutic antibodies that exploit the innate immune system to improve cancer treatment. Thanks to this study, it will be possible to correlate clinical and immunological characteristics with the patient's clinical features. The an...